为何预防复发性尿路感染未能减少肾脏瘢痕形成?对RIVUR试验的深入分析
该研究基于RIVUR试验,纳入489例在入组6个月内及至少1次随访时完成二巯基丁二酸扫描的受试者。结果显示复发性尿路感染与新肾瘢痕形成相关(OR 4.1,95%CI 2.0-8.5,p<0.01);在限定为复发性尿路感染相关新肾瘢痕时,安慰剂较抗生素预防与更高风险相关(OR 3.1,95%CI 1.0-8.8,p=0.04)。两组最终扫描瘢痕严重程度无差异(p=0.88)。
要点
- 复发性尿路感染与新肾瘢痕形成相关(OR 4.1,95%CI 2.0-8.5,p<0.01)。
- 复发性尿路感染相关新肾瘢痕在抗生素预防组5/244(2%),安慰剂组13/245(5%)。
- 安慰剂较抗生素预防与复发性尿路感染相关新肾瘢痕风险更高相关(OR 3.1,95%CI 1.0-8.8,p=0.04)。
核心结论
- 在RIVUR试验中,复发性尿路感染与新肾瘢痕形成相关。
- 当限定为复发性尿路感染相关新肾瘢痕时,抗生素预防与该结局风险降低相关。
- 为何部分无复发性尿路感染的受试者仍发生新肾瘢痕尚不清楚。
- 由于固有局限性,结果应谨慎解读。
研究设计与样本
- 基于RIVUR(Randomized Intervention for Children with Vesicoureteral Reflux)试验的二次分析。
- 纳入RIVUR试验中入组6个月内完成二巯基丁二酸扫描且至少1次随访二巯基丁二酸扫描的受试者。
- 共纳入489例患者(91%女性,平均年龄20.3个月)。
- 因事件数少,使用倾向评分校正混杂因素。
- 采用多变量逻辑回归探究协变量与结局的关联。
主要发现
- 校正年龄、性别、指数尿路感染、重复肾、膀胱肠道功能障碍和抗生素预防后,任何新肾瘢痕在复发性尿路感染患者中更常见(OR 4.1,95%CI 2.0-8.5,p<0.01)。
- 复发性尿路感染相关新肾瘢痕在抗生素预防组发生5/244(2%),在安慰剂组发生13/245(5%)。
- 校正年龄、性别、种族、指数尿路感染、膀胱肠道功能障碍、重复肾、肾积水、膀胱输尿管反流分级和基线肾瘢痕后,安慰剂较抗生素预防与复发性尿路感染相关新肾瘢痕风险更高相关(OR 3.1,95%CI 1.0-8.8,p=0.04)。
- 抗生素预防组与安慰剂组在最终二巯基丁二酸扫描的瘢痕严重程度(p=0.88)或较基线的变化(p=0.53)方面无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The RIVUR (Randomized Intervention for Children with Vesicoureteral Reflux) trial reported that antibiotic prophylaxis reduced recurrent urinary tract infection but antibiotic prophylaxis was not associated with decreased new renal scarring. However, the original reports did not assess the relationship among recurrent urinary tract infection, new renal scarring and antibiotic prophylaxis in detail. Therefore, we investigated the relationship among these issues. MATERIALS AND METHODS: We included subjects with dimercaptosuccinic acid scan within 6 months of enrollment and at least 1 followup dimercaptosuccinic acid scan from the RIVUR trial. The primary outcome was recurrent urinary tract infection associated new renal scarring, defined as recurrent urinary tract infection and new changes on dimercaptosuccinic acid scan. Due to a low number of events, propensity score was used to adjust for confounders. Multivariate logistic regression was fitted to investigate the associations between the covariates and the outcome. RESULTS: A total of 489 patients (91% female, mean age 20.3 months) were included in the study. Any new renal scarring was more common among those with recurrent urinary tract infection (OR 4.1, 95% CI 2.0-8.5, p <0.01) after adjusting for age, sex, index urinary tract infection, duplication, bowel bladder dysfunction and antibiotic prophylaxis. Recurrent urinary tract infection associated new renal scarring occurred in 5 of 244 (2%) patients on antibiotic prophylaxis and 13 of 245 (5%) on placebo. Compared to antibiotic prophylaxis, placebo was associated with a higher risk of recurrent urinary tract infection associated new renal scarring (OR 3.1, 95% CI 1.0-8.8, p=0.04) after adjusting for age, sex, race, index urinary tract infection, bowel bladder dysfunction, duplication, hydronephrosis, vesicoureteral reflux grade and baseline renal scarring. There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. CONCLUSIONS: Recurrent urinary tract infection was associated with new renal scarring in the RIVUR trial. When limited to recurrent urinary tract infection associated new renal scarring, antibiotic prophylaxis was associated with a decreased risk of this outcome. It remains unclear why new renal scarring developed in a proportion of subjects without recurrent urinary tract infection. The results should be carefully interpreted due to the inherent limitations.
引用
- Wang HH, Kurtz M, Logvinenko T, et al. Why Does Prevention of Recurrent Urinary Tract Infection not Result in Less Renal Scarring? A Deeper Dive into the RIVUR Trial. J Urol. 2019. PMID: 31026216. doi:10.1097/JU.0000000000000292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。